Multinational Suitors Queue Up As India's Paras Pharma Valuation Shoots Above $1 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
Among expected MNC bidders in the equity holding are GlaxoSmithKline, which is likely represented by Merrill Lynch; and Sanofi-Aventis, which is said to have mandated London-headquartered Rothschild to assist with its bid. Novartis and Johnson & Johnson are also considered to be potential buyers.